中国乙型肝炎登记册招募患者的基线特征和治疗方式

StephenW

J Clin Transl Hepatol. 2019 Dec 28;7(4):322-328. doi: 10.14218/JCTH.2019.00052. Epub  2019 Dec 20.
Baseline Characteristics and Treatment Patterns of the Patients Recruited to the China Registry of Hepatitis B.Shan S1, You H1, Niu J2, Shang J3, Xie W4, Zhang Y5, Li X6, Ren H7, Tang H8, Ding H9, Wang X10, Nan Y11, Dou X12, Han T13, Zhang L14, Liu X15, Deng C16, Cheng J17, Wang X18, Xie Q19, Lin S20, Huang Y21, Xu Y22, Xiong Y23, Li W24, Yan X25, Piao H26, Huang W27, Lu Q28, Gong W29, Li S30, Hu X31, Zhang X32, Liu S33, Li Y34, Yang D35, Li H36, Yang C37, Cheng M38, Zhang L39, Zheng H40, Luo X41, Lin F42, Wang L43, Xu G44, Xu X45, Wei L46, Hou J47, Duan Z48, Zhuang H49, Yang X50, Kong Y51, Jia J1; CR-HepB study group, Beijing, China.
Author information1Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis, National Clinical Research Center for Digestive Diseases, Beijing, China.2Department of Hepatology, First Hospital of Jilin University, Changchun, Jilin, China.3Department of Infectious Diseases, Henan Provincial People's Hospital, Zhengzhou, Henan, China.4Center of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.5Department of Infectious Diseases, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.6Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, Gansu, China.7Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.8Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, Sichuan, China.9Department of Gastroenterology and Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, China.10Center of Infectious Diseases, The Third People's Hospital of Taiyuan, Taiyuan, Shanxi, China.11Department of Traditional and Western Medical Hepatology, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.12Department of Infectious Diseases, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.13Department of Hepatology, Tianjin Third Central Hospital, Tianjin Medical University, Tianjin, China.14Department of Hepatology, Lanzhou University Second Hospital, Lanzhou, Gansu, China.15Department of Infectious Diseases, Peking Union Medical College Hospital, Beijing, China.16Department of Infectious Diseases, The Affiliated Hospital of Southwest Medical University, Luzhou, Gansu, China.17Department of Gastroenterology, Shanghai Public Health Clinical Center, Shanghai, China.18Department of Hepatology, Xinjiang Uygur Autonomous Region Traditional Chinese Medicine Hospital, Urumqi, Xinjiang, China.19Department of Infectious Diseases, Shanghai Ruijin Hospital, Jiao Tong University School of Medicine, Shanghai, China.20Department of Infectious Diseases, The First Affiliated Hospital of Xian Jiao Tong University, Xi'an, Shaanxi, China.21Department of Infectious Diseases, Xiangya Hospital Central South University, Changsha, Hunan, China.22Department of Digestive System, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.23Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.24Department of Infectious Diseases, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.25Department of Infectious Diseases, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Henan, China.26Department of Infectious Diseases, Yanbian University Hospital, Yanji, Jilin, China.27Department of Infectious Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.28Department of Hepatology, The Fourth People's Hospital of Qinghai Province, Xining, Qinghai, China.29Department of Infectious Diseases, Xinjiang Changji Prefecture People's Hospital, Changji, Xinjiang, China.30Department of Hepatopancreatobiliary Surgery, Affiliated Hospital of Weifang Medical University, Weifang, Shandong, China.31Department of Hepatology, Hunan Provincial People's Hospital, Changsha, Hunan, China.32Department of Gastroenterology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.33Department of Hepatology, Xixi Hospital of Hangzhou, Hangzhou, Zhejiang, China.34Department of Infectious Diseases, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China.35Department of Infectious Diseases, Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China.36Department of Hepatopancreatobiliary and Splenic Medicine, The Affiliated Hospital, Logistics University of People's Armed Police Force, Tianjin, China.37Department of Infectious Diseases, Infectious Disease Hospital of Wuhai, Wuhai, Inner Mongolia, China.38Department of Infectious Diseases, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.39Department of Infectious Diseases, The First Affiliated Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.40Department of Infectious Diseases, The Fifth Hospital of Shijiazhuang, Shijiazhuang, Hebei, China.41Department of Infectious Diseases, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China.42Department of Infectious Diseases, Hainan General Hospital, Haikou, Hainan, China.43Department of Infectious Diseases, The Second Hospital of Shandong University, Jinan, Shandong, China.44Department of Infectious Diseases, Yanan University Affiliated Hospital, Yan'an, Shaanxi, China.45Department of Infectious Diseases, Peking University First Hospital, Beijing, China.46Peking University Hepatology Institute, Peking University People's Hospital, Beijing, China.47Institute of Hepatology and Department of Infectious Disease, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.48Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.49Department of Microbiology and Infectious Disease Center, Peking University Health Science Center, Beijing, China.50The China Foundation of Hepatitis Prevention and Control, Beijing China.51Center for Clinical Epidemiology and EBM, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Diseases, Beijing, China.

AbstractBackground and Aims: Chronic hepatitis B virus (HBV) infection remains a major public health problem globally. Here, we describe the baseline characteristics and treatment profiles of HBV-infected patients recruited to the China Registry of Hepatitis B. Methods: Inclusion criteria were patients with different stages of chronic HBV infection and complete key data. Exclusion criteria were patients with hepatocellular carcinoma. The baseline clinical, laboratory and treatment profiles were analyzed. Results: Finally, 40,431 patients were included. The median age was 43 years, with 65.2% being men and 51.3% being positive for hepatitis B e antigen (HBeAg). The most common initial diagnosis was chronic hepatitis B (81.0%), followed by cirrhosis (9.3%), inactive carrier of hepatitis B surface antigen (HBsAg) (6.7%), and immune tolerant phase of hepatitis B infection (3.0%). Among the 21,228 patients who were on treatment, 88.0%, 10.0% and 2.0% received nucleos(t)ide analogues (NAs), interferon or combination of NAs and interferon, respectively. The proportion of patients who received preferred NAs (entecavir or tenofovir disoproxil fumarate) had increased from 13.5% in 2003 to 79.7% in 2016. Conclusions: We concluded that middle-aged men accounted for most of the patients with chronic hepatitis B in this cross-sectional study. About half of the patients were HBeAg-positive. NAs were the most commonly used therapy, and use of the preferred NAs had steadily increased in the past decade.

© 2019 Authors.

KEYWORDS: Hepatitis B; Registry; Treatment

PMID:31915601PMCID:PMC6943209DOI:10.14218/JCTH.2019.00052

StephenW

J临床翻译肝素。 2019年12月28日; 7（4）：322-328。土井：10.14218 / JCTH.2019.00052。 Epub 2019十二月20。
中国乙型肝炎登记册招募患者的基线特征和治疗方式
单S1，游H1，牛J2，商J3，谢W4，张Y5，李X6，任H7，唐H8，丁H9，王X10，南Y11，窦X12，韩T13，张L14，刘X15，邓C16 ，程J17，王X18，谢Q19，林S20，黄Y21，徐Y22，熊Y23，李W24，严X25，朴H26，黄W27，卢Q28，龚W29，李S30，胡X31，张X32，刘S33，李Y34，杨D35，李H36，杨C37，程M38，张L39，郑H40，罗X41，林F42，王L43，徐G44，徐X45，魏L46，侯J47，段Z48，壮H49，杨X50，孔Y51，贾J1; CR-HepB研究组，中国北京。
作者信息

1个
首都医科大学附属北京友谊医院肝脏研究中心，国家肝病消化病临床研究中心，北京市肝硬化转化医学北京市重点实验室。
2
吉林大学第一医院肝病科，吉林长春
3
河南省人民医院传染病科，河南郑州。
4
首都医科大学附属北京地坛医院肝病研究中心，北京
5
新疆医科大学附属第一医院传染病科，新疆乌鲁木齐
6
兰州大学第一医院普外科，甘肃兰州。
7
重庆医科大学附属第二医院感染科，重庆。
8
四川大学华西医院传染病中心，四川成都
9
首都医科大学附属北京佑安医院消化内科，北京
10
太原市第三人民医院传染病中心，山西太原。
11
河北医科大学第三医院中西医结合肝病科，河北石家庄
12
中国医科大学附属盛京医院传染病科，辽宁沉阳。
13
天津医科大学附属天津市第三中心医院肝科，天津，天津。
14
兰州大学第二医院肝病科，甘肃兰州
15
北京协和医院传染病科，北京。
16
西南医科大学附属医院传染病科，甘肃zhou州
17
上海市公共卫生临床中心消化内科，上海
18岁
新疆维吾尔自治区中医医院肝病科，新疆乌鲁木齐
19
上海交通大学医学院附属上海瑞金医院传染病科，上海
20
西安交通大学附属第一医院感染科，陕西西安。
二十一
中南大学湘雅医院传染病科，湖南长沙
二十二
首都医科大学附属北京天坛医院消化系统科，北京
二十三
武汉大学中南医院感染科，湖北武汉
二十四
昆明医科大学附属第一医院感染科，云南昆明。
25
徐州医科大学附属医院传染病科，河南徐州。
26
延边大学附属医院传染病科，吉林延吉
27
重庆医科大学附属第一医院传染病科，重庆。
28
青海省第四人民医院肝病科，青海西宁
29
新疆昌吉地区人民医院传染病科，新疆昌吉。
30
潍坊医科大学附属医院肝胰胆外科，山东潍坊
31
湖南省人民医院肝科，湖南长沙。
32
河北医科大学第二医院消化内科，河北石家庄
33
杭州市西溪医院肝病科，浙江杭州
34
宁夏医科大学总医院传染病科，宁夏银川。
35
华中科技大学同济医学院附属协和医院传染病科，湖北武汉。
36
    人民武装警察部队后勤大学附属医院肝胰胆脾科，天津。
37
    内蒙古乌海市乌海市传染病医院传染科。
38
    贵州医科大学附属医院传染病科，贵州贵阳
39
    山西医科大学附属第一医院感染科，山西太原。
40
    石家庄市第五医院传染病科，河北石家庄。
41
    贵州省人民医院传染病科，贵州贵阳。
42
    海南省海南省总医院感染科
43
    山东大学第二医院感染科，山东济南。
44
    延安大学附属医院传染病科，陕西延安。
45
    北京大学第一医院传染病科，北京。
46
    北京大学人民医院北京大学肝病研究所，北京
47
    南方医科大学南方医院肝病研究所，传染病科，广东广州
48
    首都医科大学附属北京佑安医院人工肝中心，北京，中国。
49
    北京大学健康科学中心微生物与传染病中心，北京。
50
    中国北京市肝炎预防控制基金会。
51
    首都医科大学附属北京友谊医院临床流行病学和循证医学研究中心，中国国家消化系统疾病研究中心。

抽象

背景与目的：慢性乙型肝炎病毒（HBV）感染仍然是全球主要的公共卫生问题。在这里，我们描述了招募到中国乙型肝炎登记处的HBV感染患者的基线特征和治疗情况。方法：纳入标准为慢性HBV感染不同阶段的患者和完整的关键数据。排除标准为肝细胞癌患者。分析了基线临床，实验室和治疗情况。结果：最后，包括40,431名患者。中位年龄为43岁，男性65.2％，乙肝e抗原（HBeAg）阳性51.3％。最常见的初始诊断是慢性乙型肝炎（81.0％），其次是肝硬化（9.3％），乙型肝炎表面抗原（HBsAg）的无效载体（6.7％）和乙型肝炎感染的免疫耐受期（3.0％）。在接受治疗的21,228例患者中，分别有88.0％，10.0％和2.0％接受了核苷酸（NA）类似物，干扰素或NA和干扰素的联合治疗。接受首选NAs（恩替卡韦或替诺福韦二吡呋酯富马酸酯）的患者比例从2003年的13.5％增加到2016年的79.7％。结论：我们得出结论：在这一十字架上，中年男性占大多数慢性乙型肝炎患者分节研究。大约一半的患者HBeAg阳性。 NAs是最常用的疗法，在过去的十年中，首选的NAs的使用稳步增长。

©2019作者。
关键字：

乙型肝炎；注册表；治疗

PMID：
    31915601
PMCID：
    PMC6943209
DOI：
    10.14218 / JCTH.2019.00052

免费全文

StephenW

http://publine.xiahepublishing.c ... JCTH.2019.00052.pdf

齐欢畅